Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer

NCT07059338 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

HER2 Positive
Colorectal Cancer (CRC)

Interventions

DRUG: Trastuzumab +Cetuximab β+Irinotecan

Sponsor

Sun Yat-sen University